Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA) on Monday announced new real-world data from the IMPACT-TD Registry showing a significant gap in diagnosing tardive dyskinesia in patients with underlying mood disorders.
The data showed that 85% of adults aged 18 to 29 with mood disorders living with tardive dyskinesia experienced moderate to severe impact from the condition, while only 23% had received a formal diagnosis.
The analysis also found that patients waited an average of more than 3.5 years to receive a formal diagnosis after involuntary movements were first recognized.
Tardive dyskinesia is a chronic movement disorder associated with certain mental health treatments and is characterized by uncontrollable and repetitive body movements.
The findings were presented at the American Psychiatric Association Annual Meeting being held May 16-20 in San Francisco.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.